ZM

Zachary J Roberts M.D.

Executive Vice President Of Research & Development And Chief Medical Officer at Allogene Therapeutics

Zachary J Roberts, MD, PhD has extensive experience in the field of medical research and development. Zachary J currently holds the position of Executive Vice President of Research & Development at Allogene Therapeutics since January 2023. Prior to this, they served as the Chief Medical Officer at Instil Bio from March 2020 to January 2023. Before that, they held multiple roles at Kite Pharma, including Vice President of Clinical Development from July 2018 to June 2019, Executive Director of Clinical Development from March 2017 to July 2018, and Director of Clinical Development from July 2015 to March 2017. Zachary J also worked at Amgen as a Medical Director in Hematology/Oncology, as well as a Senior Medical Scientist in Global Clinical Development. Zachary J began their career as a Clinical Fellow in Hematology and Oncology at Dana-Farber Cancer Institute and later served as a Resident Physician in Internal Medicine at Massachusetts General Hospital. Dr. Roberts has a strong background in medical research and development, with expertise in the areas of hematology and oncology.

Zachary J Roberts MD PhD completed their Bachelor of Science degree in Microbiology and Immunology from the University of Maryland in 1999. Zachary J then pursued further education at the University of Maryland School of Medicine from 2001 to 2009, where they obtained both a Doctor of Medicine (MD) and a Doctor of Philosophy (PhD) degree, specializing in Medicine and Immunology respectively.

In terms of additional certifications, Zachary J Roberts MD PhD obtained Board Certification in Internal Medicine from the American Board of Internal Medicine in August 2012. Zachary J also acquired certification in Medical Oncology from the same institution in October 2015.

Location

Santa Monica, United States

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Allogene Therapeutics

1 followers

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.


Industries

Employees

201-500

Links